Pivotal International Seven-Year MiSight® 1 day Contact Lens Study

CooperVision is a world leader in myopia control and management for children. They have officially announced the results of their seven-year findings for MiSight® 1 day contact lenses. Stopping MiSight 1 Day theray after 12 months showed no evidence of rebound effect in regards to axial length of the eye. This means that the prevention of more myopia didn't come back aggressively.

This study is the world’s longest continuous running soft contact lens clinical trial for myopia control. CooperVision reported that MiSight® 1 day showed sustained slowing of myopia progression across multiple years of treatment. The latest data analysis goes even deeper to illustrate that MiSight® 1 day offers a highly-desired proportional myopia control treatment effect. Abnormal axial length growth slowed by an average of approximately 50% with all tested ages (8-17). This means, introducing MiSight® 1 day at the earliest opportunity may offer the maximum cumulative benefit over time.

In the study’s seventh year, participants were transitioned from MiSight® 1 day to a single vision contact lens to evaluate if treatment gains would be retained. Myopic progression then occurred only at anticipated ‘age-normal’ levels—not at an accelerated “catch up” rate that would offset prior myopia control gains. This indicates no rebound effect.

MiSight 1 day contact lenses are specifically designed for myopia control and are FDA approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment.

Contact PersonalEyes Vision Care at 817-527-3604 and we can help your child get on track to healthier eyes!

Tags: , , , , , , , , , , , , , ,